Thus, to determine the overlap of patients with KRASG12C and activating mutations in the KEAP1-NRF2 pathway, we analyzed the genome sequencing data within the Clinical Lung Cancer Genome Project [55]. This evidence concerns the gene NFE2L2 and lung carcinoma.